Cancer combo trial ends before it begins: only one patient enrolled

NCT ID NCT06130254

Terminated Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial aimed to test the safety of combining two drugs, adagrasib and olaparib, in people with advanced solid tumors that have a specific genetic change called KRAS G12C. The study planned to include patients with certain breast, ovarian, pancreatic, and lung cancers. However, the trial was terminated after enrolling just one participant, so no useful information was gathered.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Adagrasib and olaparib
What this could lead to: If it had worked, this combination might have pointed toward a new treatment option for certain hard-to-treat cancers with a specific genetic mutation.
What could go wrong: The trial was terminated after enrolling only 1 person, so no meaningful results were obtained. It is impossible to draw any conclusions about safety or effectiveness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED BREAST CANCER WITH KRAS G12C MUTATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer exocrine pancreatic carcinoma non-small cell lung carcinoma ovarian carcinoma uterine cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOR NON-SMALL CELL LUNG CANCERS

Contacts and locations

Locations

M D Anderson Cancer Center

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.